Pipex Pharmaceuticals Announces Broadly Issued European Patent Covering Uses of Oral TRIMESTA for the Treatment of Autoimmune Diseases, Including Multiple Sclerosis

ANN ARBOR, MI--(MARKET WIRE)--Sep 6, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX:PP - News), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has received a broadly issued European patent which covers the use of estrogens in combination with other FDA-approved multiple sclerosis therapies for the treatment of autoimmune diseases.